BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zipalertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zipalertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05973773-2070@assetmemo.bio
DTSTAMP:20261121T005338Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Zipalertinib: Phase 3 readout est. (NCT05973773)
DESCRIPTION:Zipalertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RE
 ZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumo
 rs)\nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05973773
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05967689-2070@assetmemo.bio
DTSTAMP:20261121T005338Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Zipalertinib: Phase 2 readout est. (NCT05967689)
DESCRIPTION:Zipalertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer
  With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other 
 Uncommon Mutation.\nEstimated primary completion: 31 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zipalertinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05967689
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802834-2070@assetmemo.bio
DTSTAMP:20261121T005338Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zipalertinib: Phase 2 readout est. (NCT07802834)
DESCRIPTION:Zipalertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical E
 GFR-Mutant NSCLC\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07802834
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229339-2070@assetmemo.bio
DTSTAMP:20261121T005338Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Zipalertinib: Phase 2 readout est. (NCT07229339)
DESCRIPTION:Zipalertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Zi
 palertinib With Carboplatin and Pemetrexed for the Treatment of Resectable
 \, Stage II-IIIB\, Non-Small Cell Lung Cancer\nEstimated primary completio
 n: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zipal
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07229339
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128199-2070@assetmemo.bio
DTSTAMP:20261121T005338Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Zipalertinib: Phase 3 readout est. (NCT07128199)
DESCRIPTION:Zipalertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Assess Zipalertinib Versus Placebo in Participants With Early Sta
 ge NSCLC With Uncommon EGFR Mutations\, Following Complete Tumor Resection
 \nEstimated primary completion: 1 October 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07128199
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
